Share This Page
Drug Price Trends for NDC 13107-0070
✉ Email this page to a colleague
Average Pharmacy Cost for 13107-0070
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DEXTROAMP-AMPHETAMIN 10 MG TAB | 13107-0070-01 | 0.24532 | EACH | 2025-11-19 |
| DEXTROAMP-AMPHETAMIN 10 MG TAB | 13107-0070-01 | 0.23287 | EACH | 2025-10-22 |
| DEXTROAMP-AMPHETAMIN 10 MG TAB | 13107-0070-01 | 0.23396 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 13107-0070
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for the Drug NDC: 13107-0070
Introduction
The pharmaceutical landscape presents complex dynamics, particularly in analyzing market potential and pricing strategies for specific drugs. The National Drug Code (NDC) 13107-0070 pertains to a particular pharmaceutical product—most likely, a biosimilar, specialty drug, or branded medication—whose commercial viability hinges on multiple factors. This report offers a comprehensive market analysis, evaluating current demand, competitive positioning, regulatory environment, and price projections to inform stakeholders’ decision-making processes.
Product Overview and Indication
The NDC 13107-0070 corresponds to [specific drug name], indicated for [therapeutic area, e.g., oncology, autoimmune diseases, rare disorders]. This medication addresses [prevalence/incidence rates], with an existing treatment landscape characterized by [standard therapies, exclusivity periods, and unmet needs]. Its mechanism of action and therapeutic benefits position this drug as either a differentiated therapy or a biosimilar following patent expiry.
Market Landscape
- Market Size and Growth Potential
Based on latest epidemiological data, the target patient population for [drug] is estimated at [number], with a compound annual growth rate (CAGR) of [X]% over the next five years, driven by growing disease prevalence, expanding indications, and increased diagnosis rates. The global market for therapies in [indication] is projected to reach [USD amount] by 20XX, with key markets in North America, Europe, and Asia Pacific accounting for the majority share.
- Competitive Positioning
The current therapeutic environment comprises [list key competitors, branded and generic]. Given patent statuses, biosimilar entry, and recent approvals, [drug] faces competition from [name competitors or biosimilars]. Market intensity varies across regions; in mature markets, price competition and formulary placements are critical, while emerging markets present growth opportunities due to increasing healthcare access and demand.
- Regulatory Factors
Regulatory pathways influence market entry and pricing. The drug’s approval status, patent protections, and reimbursement policies in leading markets shape commercial timelines. Recent trends show accelerated approval pathways for breakthrough therapies and biosimilars, reducing time-to-market and potentially enhancing price competitiveness.
- Pricing and Reimbursement Environment
In the U.S., drug pricing is influenced by negotiations with payers, Medicaid rebates, and pharmacy benefit managers, often resulting in net prices significantly below list prices. European markets employ price-volume agreements and health technology assessments (HTAs), affecting the final price. Emerging markets employ tiered pricing strategies, often lower, but with volume-driven revenue potential.
Price Projections
- Current Price Benchmark
The current list price for [drug] ranges from [USD X] to [USD Y] per dose or treatment cycle, depending on formulation, strength, and pack size. For biosimilars or generic versions, prices are typically 15-35% below the innovator, contingent on market maturity and payer negotiations.
- Short-term Price Trends (Next 1-2 Years)
In the immediate future, prices are expected to stabilize, reflecting current procurement agreements. However, non-price factors such as formulary inclusion, patient access programs, and competition initiatives could lead to modest price erosion, estimated at [X]% annually.
- Medium to Long-term Price Projections (3-5 Years)
As biosimilar competitors enter the market, the average price could decline by [Y]%–[Z]% over 3–5 years, driven by increased competition, reduced manufacturing costs, and payer pressure for cost savings. Conversely, if the drug secures orphan drug status or limited competition persists, prices could remain relatively stable or experience slight increases, especially in markets with limited access to biosimilars.
- Impact of Regulatory and Market Dynamics
Regulatory exclusivities, such as data protection or orphan drug status, may delay biosimilar entry, maintaining higher prices longer. Conversely, policy shifts favoring biosimilar adoption and aggressive pricing strategies could accelerate price declines.
Market Entry & Revenue Potential
Given the current landscape, [drug] could generate [USD amount] in global sales within its initial 3-year window, assuming moderate market penetration, patent protections, and favorable reimbursement policies. Market expansion hinges on geographic expansion, indication approval, and payer incentives.
Strategic Considerations for Stakeholders
- Pharmaceutical Manufacturers: Focus on establishing first-mover advantages, optimizing formulary access, and engaging payers early to secure favorable reimbursement terms.
- Investors: Monitor patent protections, biosimilar activity, and regulatory policies, which significantly impact price trajectory and revenue prospects.
- Healthcare Providers: Stay informed about evolving pricing, access policies, and therapeutic alternatives to ensure cost-effective patient care.
Key Trends Affecting Future Pricing
- Biosimilar Competition: Entry of biosimilars typically drives significant price discounts, with United States biosimilar approvals increasing substantially since 2015.
- Policy and Legislation: Pushes for cost containment and biosimilar substitution policies influence retail prices.
- Market Access & Reimbursement: Payer power and formulary strategies remain central to attainable pricing models.
- Manufacturing & Supply Chain: Cost reductions in biologic manufacturing can mitigate price erosions over time.
Conclusion
The market presenting opportunities for [drug] hinges on patent lifecycle management, competitive biosimilar trajectories, and regional regulatory frameworks. While initial prices remain relatively high, widespread biosimilar adoption in key markets is expected to diminish prices over the next 3–5 years, consolidating a more competitive landscape. Stakeholders must adapt proactively to regulatory changes and market dynamics to optimize revenue streams and maintain strategic positioning.
Key Takeaways
- Market size is substantial with robust growth in indications targeted by [drug], particularly in North America and Europe.
- Pricing is currently stable but poised for decline owing to biosimilar competition and policy shifts, with projected reductions of [Y]%–[Z]% over 3–5 years.
- Regulatory exclusivity periods significantly influence initial pricing and market penetration timelines.
- Biosimilar entrants are the primary factor driving future price erosion, necessitating strategic planning for patent expirations.
- Market access strategies, including payer negotiations and formulary placements, are critical for maintaining revenue and competitive advantage.
FAQs
1. What are the key factors influencing the price of NDC 13107-0070?
Market competition, patent status, biosimilar entry, regulatory environment, and reimbursement policies are primary determinants of the drug’s price trajectory.
2. How does biosimilar competition impact pricing in this therapeutic area?
Biosimilar entry typically results in significant price reductions, often 20–35%, driving a downward pressure on list and net prices over time.
3. What regions are most promising for market expansion of this drug?
North America and Europe offer mature markets with high demand, while Asia Pacific presents promising growth opportunities due to increasing healthcare access and lower market penetration.
4. How will regulatory policies affect the future pricing of this drug?
Regulatory incentives for biosimilars and cost-containment initiatives will likely accelerate price decreases, whereas exclusivity protections sustain higher prices longer.
5. What strategic actions should stakeholders consider?
Early engagement with payers, investment in market access strategies, monitoring biosimilar development, and safeguarding patent protections are essential for optimizing market positioning and revenues.
References
- [Insert relevant market reports, regulatory filings, and industry analyses with inline citations.]
- [Example: IQVIA, "Global Biosimilar Market Report," 2022.]
- [Example: FDA, "Biosimilar Approval Summaries," 2022.]
- [Example: European Medicines Agency, "Market Access & Pricing Policies," 2022.]
- [Example: Industry news outlets covering recent biosimilar launches and regulatory updates.]
More… ↓
